MarketPulse
A

$AAPG

3 articles found
2 positive
0 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Ascentage Pharma Group International

Ascentage Pharma Showcases Pipeline at ASCO 2026 With Three Oral Presentations

Ascentage Pharma selected for six abstracts at ASCO 2026, including three rapid oral presentations featuring data on three key oncology drug candidates.
AAPGclinical trialsoncology
GlobeNewswire Inc.GlobeNewswire Inc.··Ascentage Pharma Group International

Ascentage Pharma's Revenue Surges 90% on Olverembatinib, Lisaftoclax Growth

Ascentage Pharma reports 90% revenue growth to $82.1M in 2025, driven by Olverembatinib and newly launched Lisaftoclax, despite $177.7M net loss.
AAPGbiopharmaceuticalcancer therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Ascentage Pharma Group International

Ascentage Pharma Sets March 25 Earnings Call for 2025 Full-Year Results

Ascentage Pharma will report 2025 full-year unaudited results on March 25, 2026, with dual-language investor webcasts highlighting performance of its approved cancer therapies and clinical pipeline progress.
AAPGfinancial resultsclinical trials